UBS Group
MRTX

UBS Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

UBS Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,945
Closed -$3.05M – 10417
2023
Q4 		$3.05M Buy
51,945
+18,863
+57% +$1.06M ﹤0.01% 3339
2023
Q3 		$1.44M Sell
33,082
-91,686
-73% -$3.27M ﹤0.01% 3773
2023
Q2 		$4.51M Buy
124,768
+43,336
+53% +$1.79M ﹤0.01% 2701
2023
Q1 		$3.03M Sell
81,432
-58,300
-42% -$2.62M ﹤0.01% 2989
2022
Q4 		$6.33M Buy
139,732
+118,286
+552% +$7.65M ﹤0.01% 2267
2022
Q3 		$1.5M Sell
21,446
-28,316
-57% -$2.1M ﹤0.01% 3414
2022
Q2 		$3.34M Buy
49,762
+41,731
+520% +$2.65M ﹤0.01% 2712
2022
Q1 		$660K Sell
8,031
-31,607
-80% -$3.23M ﹤0.01% 4480
2021
Q4 		$5.82M Buy
39,638
+10,732
+37% +$1.67M ﹤0.01% 2663
2021
Q3 		$5.11M Buy
28,906
+23,810
+467% +$3.83M ﹤0.01% 2648
2021
Q2 		$823K Sell
5,096
-4,936
-49% -$793K ﹤0.01% 4348
2021
Q1 		$1.72M Sell
10,032
-4,258
-30% -$843K ﹤0.01% 3723
2020
Q4 		$3.14M Buy
14,290
+1,725
+14% +$373K ﹤0.01% 2934
2020
Q3 		$2.09M Sell
12,565
-12,148
-49% -$1.66M ﹤0.01% 3001
2020
Q2 		$2.82M Buy
24,713
+8,959
+57% +$869K ﹤0.01% 2557
2020
Q1 		$1.21M Sell
15,754
-2,226
-12% -$200K ﹤0.01% 3196
2019
Q4 		$2.32M Sell
17,980
-64,876
-78% -$6.26M ﹤0.01% 3406
2019
Q3 		$6.46M Buy
82,856
+62,322
+304% +$5.85M ﹤0.01% 2143
2019
Q2 		$2.12M Buy
20,534
+17,510
+579% +$1.36M ﹤0.01% 3098
2019
Q1 		$221K Sell
3,024
-171,857
-98% -$11.7M ﹤0.01% 4542
2018
Q4 		$7.42M Buy
174,881
+145,857
+503% +$5.81M ﹤0.01% 1830
2018
Q3 		$1.37M Buy
29,024
+26,524
+1,061% +$1.48M ﹤0.01% 3545
2018
Q2 		$123K Sell
2,500
-57,943
-96% -$2.19M ﹤0.01% 5293
2018
Q1 		$1.85M Buy
60,443
+35,233
+140% +$978K ﹤0.01% 3204
2017
Q4 		$460K Buy
25,210
+10,620
+73% +$165K ﹤0.01% 4355
2017
Q3 		$171K Sell
14,590
-10,701
-42% -$61.9K ﹤0.01% 4955
2017
Q2 		$93K Buy
25,291
+2,796
+12% +$10.7K ﹤0.01% 5217
2017
Q1 		$117K Sell
22,495
-4,745
-17% -$26K ﹤0.01% 4987
2016
Q4 		$130K Buy
27,240
+5,737
+27% +$31.2K ﹤0.01% 5107
2016
Q3 		$142K Sell
21,503
-494
-2% -$2.63K ﹤0.01% 4773
2016
Q2 		$120K Buy
21,997
+1,931
+10% +$30.8K ﹤0.01% 4904
2016
Q1 		$429K Sell
20,066
-19,029
-49% -$426K ﹤0.01% 3893
2015
Q4 		$1.24M Buy
39,095
+22,413
+134% +$792K ﹤0.01% 3239
2015
Q3 		$575K Sell
16,682
-1,636
-9% -$49.5K ﹤0.01% 3785
2015
Q2 		$576K Sell
18,318
-1,513
-8% -$44.6K ﹤0.01% 3994
2015
Q1 		$581K Buy
19,831
+8,071
+69% +$189K ﹤0.01% 4025
2014
Q4 		$218K Buy
+11,760
New +$198K ﹤0.01% 4974

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's MRTX Position: Q1 2024 in Review

UBS Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 51,945 shares — an estimated $3.05M sold.

UBS Group first reported a position in MRTX in Q4 2014 and held it in 37 quarters. The position peaked at $7.42M in Q4 2018. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • UBS Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 51,945 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.05M.
  • UBS Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2014 and held it in 37 quarters.
  • UBS Group's Mirati Therapeutics, Inc. Common Stock position peaked at $7.42M in Q4 2018.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.